Clinical Trial VICCPHI1231


Phase 1/2 Study of PI-3K Inhibition with PX-866 Combined with Vemurafenib (BRAF Inhibitor) in Patients with BRAF-Mutant Cancer Including Advanced Melanoma

Principal Investigator(s)

Jeffrey Sosman


  • Protocol No. VICCPHI1231
  • Open Date: 11/19/2012
  • Staging: Phase I/II
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the safety and tolerability of PX-866 in combination with twice daily oral administration of vemurafenib in patients with any advanced BRAF-mutant cancer
  • Disease Sites: Melanoma
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: PLX4032; PX-866; RO5185426 (Vemurafenib); Vemurafenib
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01616199
  • Secondary Protocol No: PX-866-007



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.